FLVCR2 and breast carcinoma: As shown in Fig. 5A, only AIB1, and not ERα, was identified in the protein complex by using anti-CCTη or anti-CCTζ antibodies for immunoprecipitation, suggesting that chaperonin CCT could potentially interact with AIB1 in breast cancer cells.